Hospira
Encyclopedia
Hospira, Inc. is a U.S.-based global pharmaceutical and medical device
company with headquarters in Lake Forest, Illinois
. It has approximately 14,000 employees. Hospira is the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Worldwide sales in 2010 were approximately $3.9 billion.
(ABT) said that it decided to spin off Hospira as a separate company so that the new company could focus on products to be primarily used in a hospital setting and to allow Abbott to focus on core areas of strength.
Hospira's name was picked by employee vote. The name is derived from the words hospital, spirit, inspire and the Latin word "spero," which means "hope." Hospira became an independent company on Monday, May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.
In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion. The deal expanded Hospira's international reach and its presence in the oncology market.
More recent acquisitions by Hospira include the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, announced in late 2009 and completed in 2010; Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million, in 2010; and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009.
In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball replaced founding CEO Chris Begley, who in 2010 had announced his plans to retire from the CEO position and remain at Hospira as executive chairman. Ball joined the company in March 2011.
is an anesthetic discovered by Hospira's parent company, Abbott Laboratories and manufactured by Hospira after it was spun off. The WHO
considers it an essential drug. However, it is also used as part of the lethal injection
protocol in many US states. Though Hospira has supplied these states with the drug, it has said, "we do not support the use of any of our products in capital punishment procedures."
On January 21, 2011, the company announced that it would stop producing sodium thiopental, citing a new Italian law requiring exports of the drug not be used for capital punishment; the company's manufacturing facility for sodium thiopental is located in Liscate
, Italy.
Biosimilars: In 2010, the U.S. Congress passed legislation that would allow the marketing of biosimilar drugs in the United States. The legislation would allow 12 years of data exclusivity for brand-name biologics. Some consumer groups, like AARP, oppose this provision, saying it would cause lack of access to the promise of such drugs.
Medical device
A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery . Whereas medicinal products achieve their principal action by pharmacological, metabolic or immunological means. Medical devices act by other means like physical, mechanical, thermal,...
company with headquarters in Lake Forest, Illinois
Lake Forest, Illinois
Lake Forest is an affluent city located in Lake County, Illinois, United States. The city is south of Waukegan along the shore of Lake Michigan, and is a part of the Chicago metropolitan area and the North Shore. Lake Forest was founded around Lake Forest College and was laid out as a town in...
. It has approximately 14,000 employees. Hospira is the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Worldwide sales in 2010 were approximately $3.9 billion.
History
In 2003, Abbott LaboratoriesAbbott Laboratories
Abbott Laboratories is an American-based global, diversified pharmaceuticals and health care products company. It has 90,000 employees and operates in over 130 countries. The company headquarters are in Abbott Park, North Chicago, Illinois. The company was founded by Chicago physician, Dr....
(ABT) said that it decided to spin off Hospira as a separate company so that the new company could focus on products to be primarily used in a hospital setting and to allow Abbott to focus on core areas of strength.
Hospira's name was picked by employee vote. The name is derived from the words hospital, spirit, inspire and the Latin word "spero," which means "hope." Hospira became an independent company on Monday, May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.
In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion. The deal expanded Hospira's international reach and its presence in the oncology market.
More recent acquisitions by Hospira include the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, announced in late 2009 and completed in 2010; Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million, in 2010; and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009.
In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball replaced founding CEO Chris Begley, who in 2010 had announced his plans to retire from the CEO position and remain at Hospira as executive chairman. Ball joined the company in March 2011.
Pharmaceuticals
- AzithromycinAzithromycinAzithromycin is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics...
- Biosimilars
- BupivacaineBupivacaineBupivacaine is a local anaesthetic drug belonging to the amino amide group. AstraZeneca commonly markets it under various trade names, including Marcain, Marcaine, Sensorcaine and Vivacaine.-Indications:...
- CefazolinCefazolinCefazolin , also known as cefazoline or cephazolin, is a first-generation cephalosporin antibiotic.The drug is usually administrated by either intramuscular injection or intravenous infusion .-Indications:Cefazolin is mainly used to treat bacterial infections of the skin...
- CiprofloxacinCiprofloxacinCiprofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class.It is a second-generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops synthesis of DNA and of...
- Claforan
- ClindamycinClindamycinClindamycin rINN is a lincosamide antibiotic. It is usually used to treat infections with anaerobic bacteria but can also be used to treat some protozoal diseases, such as malaria...
- CytarabineCytarabineCytarabine, or cytosine arabinoside, is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia and non-Hodgkin lymphoma. It is also known as Ara-C...
- Docetaxel
- ErythropoietinErythropoietinErythropoietin, or its alternatives erythropoetin or erthropoyetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production...
- ErythromycinErythromycinErythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and...
- FilgrastimFilgrastimFilgrastim is a granulocyte colony-stimulating factor analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology. The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of Escherichia coli. ...
- Gemcitabine
- GentamicinGentamicinGentamicin is an aminoglycoside antibiotic, used to treat many types of bacterial infections, particularly those caused by Gram-negative organisms. However, gentamicin is not used for Neisseria gonorrhoeae, Neisseria meningitidis or Legionella pneumophila...
- HeparinHeparinHeparin , also known as unfractionated heparin, a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule...
- IrinotecanIrinotecanIrinotecan is a drug used for the treatment of cancer.Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin....
- MeropenemMeropenemMeropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals...
- MorphineMorphineMorphine is a potent opiate analgesic medication and is considered to be the prototypical opioid. It was first isolated in 1804 by Friedrich Sertürner, first distributed by same in 1817, and first commercially sold by Merck in 1827, which at the time was a single small chemists' shop. It was more...
- OndansetronOndansetronOndansetron is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic , often following chemotherapy. Its effects are thought to be on both peripheral and central nerves...
- OxaliplatinOxaliplatinOxaliplatin is a coordination complex that is used in cancer chemotherapy. These platinum-based drugs are usually classified as alkylating agents, although they are not actually alkylating groups ....
- PaclitaxelPaclitaxelPaclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol...
- Piperacillin/tazobactamPiperacillin/tazobactamPiperacillin/tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the β-lactamase inhibitor tazobactam. It is marketed as Kilbac by Morepen and Tazocin or, in the USA, as Zosyn by Wyeth Pharms Inc .-External links:*...
- Precedex (dexmedetomidineDexmedetomidineDexmedetomidine is a sedative medication used by intensive care units and anesthetists. It is relatively unique in its ability to provide sedation without causing respiratory depression...
hydrochloride injection) - PropofolPropofolPropofol is a short-acting, intravenously administered hypnotic agent. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. Propofol is also commonly used in veterinary medicine...
- Tobramycin
- TopotecanTopotecanTopotecan hydrochloride is a chemotherapy agent that is a topoisomerase I inhibitor. It is the water-soluble derivative of camptothecin...
- VancomycinVancomycinVancomycin INN is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed, although the emergence of...
- VisIV
Medical Devices
- EndoTool
- GemStar SP
- Hospira MedNet software
- LifeCare PCA
- LifeShield
- Plum A+
- Symbiq
- TheraDoc
Product Descriptions
- Biosimilars: Hospira received marketing approval from the European Commission in December 2007 for its biosimilar drug, Retacrit. Retacrit is an erythropoietin, or EPO, for the treatment of anemia associated with chronic renal failure and chemotherapy. The European Union has developed a regulatory pathway to approve biosimilars in Europe, but a comparable U.S. Food and Drug Administration (FDA) clearance system does not yet exist. Hospira launched Retacrit in Europe in early 2008 and today sells the product in all major European markets. In 2010, Hospira received approval and launched in Europe its second biosimilar, Nivestim, a generic filgrastim for the prevention of febrile neutropenia. Hospira also received approval for Nivestim in Australia in 2010, and launched the product in Australia in 2011. To date, Hospira is the only United States-based company selling biosimilars in Europe. Hospira announced in 2010 the start of a U.S. trial for biosimilar EPO.
- Hospira MedNet: Hospira MedNet is a customizable system that helps hospitals define medication dose limits and track intravenous drug deliveries to help prevent errors.
- Precedex: Precedex (dexmedetomidine hydrochloride) is Hospira's proprietary I.V. sedative, and is a relatively selective alpha-2-adrenoceptor agonist. In the United States, it is approved for continuous I.V. sedation of initially intubated and mechanically ventilated patients in the intensive care setting for use up to 24 hours. Precedex has shown promise as a sedative agent for ICU patients and may decrease the occurrence of a combined end point of delirium and coma. In 2010, Hospira received approval in Japan for long-term use (greater than 24 hours) of Precedex.
- Symbiq: Symbiq is an infusion system that administers intravenous (I.V.) medications, fluids and solutions to patients. It is designed to reduce the risk of infusion-related medical errors.
- VisIV: VisIV is an intravenous (I.V.) solution bag free of polyvinyl chloride (PVC) materials that can damage the environment and of the so-called plastic "overwrap" that covers the IV bag during shipping to prevent moisture evaporation and keep the medication concentrated.
Sodium thiopental production
Sodium thiopentalSodium thiopental
Sodium thiopental, better known as Sodium Pentothal , thiopental, thiopentone sodium, or Trapanal , is a rapid-onset short-acting barbiturate general anaesthetic...
is an anesthetic discovered by Hospira's parent company, Abbott Laboratories and manufactured by Hospira after it was spun off. The WHO
Who
Who may refer to:* Who , an English-language pronoun* who , a Unix command* Who?, one of the Five Ws in journalism- Art and entertainment :* Who? , a 1958 novel by Algis Budrys...
considers it an essential drug. However, it is also used as part of the lethal injection
Lethal injection
Lethal injection is the practice of injecting a person with a fatal dose of drugs for the express purpose of causing the immediate death of the subject. The main application for this procedure is capital punishment, but the term may also be applied in a broad sense to euthanasia and suicide...
protocol in many US states. Though Hospira has supplied these states with the drug, it has said, "we do not support the use of any of our products in capital punishment procedures."
On January 21, 2011, the company announced that it would stop producing sodium thiopental, citing a new Italian law requiring exports of the drug not be used for capital punishment; the company's manufacturing facility for sodium thiopental is located in Liscate
Liscate
Liscate is a comune in the Province of Milan in the Italian region Lombardy, located about 20 km east of Milan.-External links:*...
, Italy.
Legislation and Litigation
Oxaliplatin: In August 2009, Hospira introduced a generic version of Sanofi-Aventis SA's (SNY) colon-cancer drug known generically as oxaliplatin and by the brand name Eloxatin, in the United States. In April 2010, Hospira announced a legal settlement with Sanofi-Aventis. Under the settlement terms, Hospira agreed to stop selling oxaliplatin injection in the United States by June 30, 2010, and can relaunch the product in the United States on Aug. 9, 2012.Biosimilars: In 2010, the U.S. Congress passed legislation that would allow the marketing of biosimilar drugs in the United States. The legislation would allow 12 years of data exclusivity for brand-name biologics. Some consumer groups, like AARP, oppose this provision, saying it would cause lack of access to the promise of such drugs.